Alisertib

Puma Biotechnology reports Q3 2024 net income of $20.3M, up from $5.8M in Q3 2023, driven by increased product revenue from NERLYNX®. The company anticipates key milestones in alisertib clinical trials for breast and lung cancer. Puma also provides financial outlook for Q4 2024 and full-year 2024.

Puma Biotechnology's Q3 2024 earnings show a significant increase in net income and total revenue, driven by robust NERLYNX sales and higher royalty revenue. Key metrics include a 9% rise in product revenue to $56.1 million, net income of $20.3 million ($0.41 per share), and total revenue of $80.5 million. The company holds $97 million in cash and is advancing its alisertib development for cancer treatment.

Puma Biotechnology reports $56.1M net NERLYNX revenue in Q3'24, a ~9% increase from Q3'23 and ~26% from Q2'24. 2,723 ex-factory bottles sold, a ~5% decline from Q3'23 but an ~8% increase from Q2'24. ~65% of patients started at a reduced dose. Forward-looking statements involve risks, including COVID-19 impact and regulatory filings.

Puma Biotechnology granted a non-executive employee 5,625 restricted stock units, vesting over three years under the 2017 Employment Inducement Incentive Award Plan.

Puma Biotechnology granted a 5,625-share restricted stock unit award to a new non-executive employee on Nov 4, 2024, under its 2017 Employment Inducement Incentive Award Plan, vesting over three years.